Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Sickle Cell Disease
Interventions: Oxbryta® (voxelotor) 500-mg Tablets; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Farmington, Connecticut • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Sickle Cell Disease, Pregnancy Related
Interventions: Prophylactic Transfusion Intervention group: Transfusion, Control group; Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Crisis, Sickle Cell Disease
Interventions: Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease
Interventions: Osivelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 46
States / cities: Mobile, Alabama • Hartford, Connecticut • New Haven, Connecticut + 27 more

Conditions: Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions: Alefacept; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anemia, Sickle Cell
Interventions: Types of Telemedicine Delivery Models; Other
Lead sponsor: Indiana University; Other
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sickle Cell Disease, Chronic Pain
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 16 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sickle Cell Disease
Interventions: Mobile DOT; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Chronic Hemolytic Disorders
Interventions: Sodium Nitrite Cream; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 2
States / cities: Bethesda, Maryland • Fairfax, Virginia

Conditions: Sickle Cell Disease
Interventions: Prasugrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, SCD
Interventions: Fludarabine, Hematopoietic Stem Cell Transplant (HSCT); Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease
Interventions: Voxelotor Oral Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: St Louis, Missouri • The Bronx, New York

Conditions: Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Interventions: CTX001; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Charlotte, North Carolina • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Sickle Cell Disease, Sickle Cell Trait
Interventions: Healthy volunteers without SCT, Healthy volunteers with SCT, Volunteers with SCD; Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Interventions: needling acupuncture, laser acupuncture; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 14 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Kidney Injury
Interventions: SCD-F40; Device
Lead sponsor: CytoPherx, Inc; Industry
Eligibility: 2 Years to 22 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Birmingham, Alabama • Atlanta, Georgia • Ann Arbor, Michigan + 1 more

Conditions: Sickle Cell Disease
Interventions: Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus; Procedure · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 16 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis, Ketamine, Intranasal Ketamine, Analgesia
Interventions: Intranasal ketamine; Drug
Lead sponsor: Abigail Nixon; Other
Eligibility: 3 Years to 25 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Sickle Cell Disease
Interventions: Red blood cell exchange in sickle cell; Device
Lead sponsor: Terumo BCT; Industry
Eligibility: 12 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Oakland, California • Aurora, Colorado + 2 more

Conditions: Sudden Cardiac Death
Interventions: Arm 1 (ATP+Shock), Arm 2 (shock only); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 2,692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 89
States / cities: Huntsville, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more

Conditions: Sickle Cell Disease
Interventions: Music Therapy; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 23 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Retrospective Real World Oxbryta® Data Collection and Analysis Study

Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

Telemedicine for Children With Sickle Cell Disease

Use of a Mobile-based App for SCD Patients

Functional Neuroimaging of Pain Using EEG and fMRI

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease

Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Voxelotor Brain Oxygenation and Neurocognitive Study

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Sickle Cell Hemoglobinopathies and Bone Health

Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI).

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

Music Therapy in Sickle Cell Transition Study